MLchartDataset catalogue

pozelimab

Term · Oncology and biomedicine · MLC-T-ONC-016193

A human immunoglobulin G4 (IgG4) monoclonal antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, pozelimab targets and binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). C5, a complement pathway protein, is expressed at high levels by the liver.

Table 1. Record
IdentifierMLC-T-ONC-016193
FieldOncology and biomedicine
SynonymsWHO 10945
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-016193",
  "term": "pozelimab",
  "field": "Oncology and biomedicine",
  "definition": "A human immunoglobulin G4 (IgG4) monoclonal antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, pozelimab targets and binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). C5, a complement pathway protein, is expressed at high levels by the liver.",
  "synonyms": [
    "WHO 10945"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pozelimab/"
}

Record 13,537 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.